TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02532439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXA
Description: The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXA
Description: The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pQCT
Description: Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pQCT
Description: Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
Study: NCT01480544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Treatment 1
Description: Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Treatment 2
Description: Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
Study: NCT04131842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External focus of attention visual feedback
Description: Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External focus of attention auditory feedback
Description: Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal focus of attention video feedback
Description: Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No feedback
Description: Patients will receive no feedback during the impairment-based rehabilitation program.
Study: NCT03206008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study: NCT03913559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: dose: 0.5 mg/m2 IV over 60 minutes, days: 1, 8 and 15 every 4 weeks (28 days per cycle) for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intrathecal (IT) therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Intrathecal (IT) therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intrathecal (IT) therapy
Study: NCT02367222

Intervention type: OTHER
Intervention: Exposed to Arepanrix™ Cohort
Description: Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..

Intervention type: OTHER
Intervention: Unexposed to Arepanrix™ Cohort
Description: Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.
Study: NCT02941536

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Circulating tumor cells evaluation
Description: Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.
Study: NCT02569515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Beta
Description: Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
Study: NCT02265913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir 5 percent (Perrigo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir 5 percent (Reference)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Study: NCT00042809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03127449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alflutinib
Description: patients take Alflutinib orally once per day at different dose
Study: NCT01377493

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: chewing gum
Description: chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
Study: NCT03156530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupunture
Description: Evaluation of balance before, during and after applying of auricular acupuncture.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Not receive stimulation.
Study: NCT00075881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT01149200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-6499
Description: 5mg enteric-coated oral hard gelatin capsule, administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo as enteric-coated oral hard gelatin capsule, administered twice daily
Study: NCT00460993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunesta
Description: Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4.
Study: NCT02323334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part A, B, C)
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part A, B, C)
Description: administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part A, B, C)
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part A, B, C)
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part A, B, C)
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part A, B, C)
Description: administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part A, B, C)
Description: administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part A, B, C)
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: administered orally
Study: NCT00748800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Management
Description: 5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Promotion
Description: 5 session group focused on delivering general health promotion information in didactic format
Study: NCT04398966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Artery Embolization (HydroPearl® compressible microspheres)
Description: Embolic material
Study: NCT02557789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefamulin
Description: Lefamulin administered iv or orally in the fasted state and orally in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefamulin
Description: Lefamulin administered iv or orally in the fasted state and orally in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefamulin
Description: Lefamulin administered iv or orally in the fasted state and orally in the fed state
Study: NCT03552705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
Study: NCT01978275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulong 100, pajunk, germany
Description: simulating catheter
Study: NCT03913559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 1 mg/kg (max 50 mg) IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 10 mg/kg (max 650 mg) PO x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1 mg/kg IV x 1
Study: NCT02557789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefamulin
Description: Lefamulin administered iv or orally in the fasted state and orally in the fed state
Study: NCT01617967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patisiran
Description: Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks \[Q3W\]: Day 0 and Day 21) and an alternative premedication regimen.
Study: NCT01552317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OxSalt care bundle
Description: A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
Study: NCT03070119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Participants will receive a loading dose regimen followed by maintenance dosing.
Study: NCT05956925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.
Description: The investigators showed participants how to use the Health Mate app, upload Withings BP cuff readings, upload historical data to the cloud, read trend lines in their record, rank their daily motivational level, and answer a brief short message service (SMS) question about whether the participants completed the behavioral change task encouraged by the daily message. A one-page instruction sheet with the research team's contact information was provided. Participants were instructed to take their BP daily, before their first meal and encouraged to avoid prior alcohol and caffeine intake as well as physical activity. The participants were instructed to rate their motivational level as low, moderate, or high via SMS when transmitting their BP value. Their level will trigger the appropriate behavioral change SMS prompt.
Study: NCT02891980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26 Zaire Ebola Vaccine
Description: A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26 Zaire Ebola Vaccine
Description: A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26 Zaire Ebola Vaccine
Description: A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Multi-Filo Ebola Vaccine
Description: A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Multi-Filo Ebola Vaccine
Description: A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Multi-Filo Ebola Vaccine
Description: A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
Study: NCT05514431

Intervention type: PROCEDURE
Intervention: Epidural
Description: Traditional epidural catheter placement

Intervention type: PROCEDURE
Intervention: Dural Puncture Epidural (DPE) technique
Description: Epidural catheters placed via DPE technique

Intervention type: PROCEDURE
Intervention: Combined Spinal-Epidural (CSE) technique
Description: Epidural catheters placed via CSE technique
Study: NCT01863745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib was administered daily as hard gelatin capsules for oral use. The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
Study: NCT00418145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megadose oral methylprednisolone
Description: 1400 mg qd/5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone
Description: 1000 mg/qd/5 days
Study: NCT04038125

Intervention type: DRUG
Group type: OTHER
Intervention: Ozurdex Drug Implant Product
Description: Intravitreal Ozurdex injection
Study: NCT04033913

Intervention type: OTHER
Intervention: Self questionnaire
Description: Patients who have successfully perform self-catheterization complete a self questionnaire on the importance of each criterion in choosing the catheter they have made.
Study: NCT04195412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS + upper limb rehabilitation
Description: Stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. Stimulation intensity will be 2 mA with current ramping up and down of 10 seconds each. The stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS + upper limb rehabilitation
Description: Sham stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each sham stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. The anode will be placed to the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off automatically after 30 seconds. The sham stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
Study: NCT04136301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informative Video group
Description: Informative Video group before labor in nulliparous women
Study: NCT02591303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress reactions measurement during stressful and neutral driving sessions
Description: Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress reactions measurement during stressful and neutral driving sessions
Description: Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
Study: NCT00169260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational counseling
Description: behavioral motivational counselling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01406912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recreational Activity
Description: Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Gaming System Arm
Description: Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
Study: NCT00989027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergonovine
Description: Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboprost
Description: Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin and Ergonovine
Description: Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin and Carboprost
Description: Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Study: NCT00744835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation procedure and/or cardioversion
Description: Ablation Frontiers Cardiac Ablation System
Study: NCT04732585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy or Surgery
Description: Physiotherapy: Guidelines suggest a tailored and progressive exercise program to improve muscle strength and control, joint mobility, and patient understanding of the problem and how to manage it. Additional interventions like tape or manual treatment can also be implemented but should not be exclusive~Surgery: ACL surgical reconstruction
Study: NCT02500355

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Release via limited approaches
Description: Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Release via standard approach
Description: Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic Carpal Tunnel Release
Description: Carpal tunnel release under endoscope.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: endoscope or an arthroscopic device
Study: NCT00973973

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Immediate release (IR) tablets taken orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix
Description: Immediate release (IR) tablets taken orally once a day
Study: NCT01290250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice based beverage enriched in polyphenols
Description: 2 daily doses (250 ml each) during 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orange juice based beverage enriched in polyphenols
Description: 2 daily doses (250 ml each) during 3 months
Study: NCT01716195

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy followed by Response Adapted Chemoradiation
Description: All patients receive induction chemotherapy with 2 cycles of paclitaxel and carboplatin followed by response adapted, de-escalated chemoradiation. Patients with a complete or partial response will receive 54 Gy with concurrent paclitaxel and patients with stable disease will receive 60 Gy with concurrent paclitaxel.